Ana Maria Alonso Torres

Instituto de Investigación Biomédica de Málaga

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Jose Maria Rumbo-Prieto

Profesor Asociado

Universidade da Coruña

SPAIN

View details

Eduardo Aguera-Morales

Profesor Asociado

Universidad de Córdoba

SPAIN

View details

LAURA NAVARRO CANTO

PROFESORA ASOCIADA

Universitat de Miguel Hernández d'Elx

SPAIN

View details

Luis Brieva Ruiz

Head of the department

Hospital Universitari Arnau de Vilanova

SPAIN

View details

Alessandro Dinoto

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ana Maria Alonso Torres

Research Interests

Explore related searches

Contact this professor

Articles (19)

Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis.

Economic burden of secondary progressive multiple sclerosis: DISCOVER study.

Patient experience in healthcare interventions: PROM and PREM evaluation in patients with multiple sclerosis after switching administration route of natalizumab

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.

Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study.

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale.

Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis.

Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023,Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023

Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management

Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.

[Family planning in men and women with multiple sclerosis. Analysis of the Andalusian Registry (2018-2022)].

Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach.

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

15<sup>th</sup> Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I),XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

Collaborators (5)

Jose Maria Rumbo-Prieto

Eduardo Aguera-Morales

LAURA NAVARRO CANTO

Luis Brieva Ruiz

Alessandro Dinoto

Make your next move.